Shared by James Harvey
(ISSUP staff) - 3 September 2024
Format
Video and audio recordings
Published by / Citation
Penington Institute
This webinar hosted by the Penington Institute to Mark International Overdose Awareness Day 2024 brings together a panel with diverse perspectives, insights, experiences, research, and solutions to the overdose crisis.
This guide was drawn from HEALing Communities Study (HCS) learnings to-date and expert insights to provide guidance regarding implementation of ORCCA menu strategies.
SAMHSA’s updated Overdose Prevention and Response Toolkit provides guidance to a wide range of individuals on preventing and responding to an overdose. The toolkit also emphasizes that harm reduction and access to treatment are essential aspects of overdose prevention.
The toolkit, designed to augment overdose prevention and reversal training, provides guidance on the role of opioid overdose reversal medications, including naloxone and nalmefene, and how to respond to an overdose. It also contains appendices for specific audiences, including people who use drugs (PWUD), people who take...
Shared by James Harvey
(ISSUP staff) - 1 July 2024
Format
Report
Published by / Citation
UNODC
A global reference on drug markets, trends and policy developments, the World Drug Report offers a wealth of data and analysis and in 2024 comprises several elements tailored to different audiences.
Druckrey-Fiskaaen, K.T., Vold, J.H., Madebo, T. et al. Liver stiffness and associated risk factors among people with a history of injecting drugs: a prospective cohort study. Subst Abuse Treat Prev Policy 19, 21 (2024). https://doi.org/10.1186/s13011-024-00603-z
Background:
People who have problems with using opioids or other drugs and inject them have shorter lives than most people. Liver diseases, especially, contribute to this. Checking liver stiffness might help find liver problems early. This study looks at how common liver disease is in people who use drugs and how different factors like types of drugs used, hepatitis C, alcohol, weight, age, diabetes, and cholesterol affect liver stiffness.
Methods:
From May 2017 to March 2022, data was collected from 676 people in Western Norway. Most were getting treatment for opioid addiction, while...
Rodríguez, M.N., Colgan, D.D., Leyde, S. et al. Trauma exposure across the lifespan among individuals engaged in treatment with medication for opioid use disorder: differences by gender, PTSD status, and chronic pain. Subst Abuse Treat Prev Policy 19, 25 (2024). https://doi.org/10.1186/s13011-024-00608-8
Background
There is little research on lifetime trauma exposure among individuals undergoing medication treatment for opioid use disorder (MOUD). A multisite study examined the prevalence of lifetime trauma and explored differences based on gender, PTSD status, and chronic pain.
Methods
A cross-sectional study examined baseline data from participants (N = 303) enrolled in a randomised controlled trial of a mind–body intervention as an adjunct to MOUD. All participants were stabilised on MOUD. Measures included the Trauma Life Events Questionnaire (TLEQ), the Brief Pain Inventory (BPI)...
Furulund, E., Carlsen, SE.L., Druckrey-Fiskaaen, K.T. et al. A qualitative study of experiences with physical activity among people receiving opioid agonist therapy. Subst Abuse Treat Prev Policy 19, 26 (2024). https://doi.org/10.1186/s13011-024-00607-9
Background
Physical or mental health commorbidities are common among people with substance use disorders undergoing opioid agonist therapy. Exercise provides many health benefits and can be used both as a preventive and treatment strategy. However, exercise programs for people with substance use disorders on opioid agonist therapy are limited. This study aims to explore their experiences with physical activity, as well as the perceived barriers and facilitators.
Method
Fourteen qualitative interviews were conducted with individuals receiving opioid agonist therapy in outpatient...
Furulund, E., Carlsen, SE.L., Druckrey-Fiskaaen, K.T. et al. A qualitative study of experiences with physical activity among people receiving opioid agonist therapy. Subst Abuse Treat Prev Policy 19, 26 (2024). https://doi.org/10.1186/s13011-024-00607-9
Background:
Many people with substance use disorders undergoing opioid agonist therapy often have physical or mental health commorbidities. Exercise is recognised as beneficial for both prevention and treatment of various health conditions, yet exercise interventions for this population are limited. This study aims to explore the experiences, perceived barriers, and facilitators of physical activity among individuals receiving opioid agonist therapy.
Method:
Qualitative interviews were conducted with fourteen individuals receiving opioid agonist therapy in outpatient clinics in...
Rodríguez, M.N., Colgan, D.D., Leyde, S. et al. Trauma exposure across the lifespan among individuals engaged in treatment with medication for opioid use disorder: differences by gender, PTSD status, and chronic pain. Subst Abuse Treat Prev Policy 19, 25 (2024). https://doi.org/10.1186/s13011-024-00608-8
There is little study of lifetime trauma exposure among individuals engaged in medication treatment for opioid use disorder (MOUD). A multisite study provided the opportunity to examine the prevalence of lifetime trauma and differences by gender, PTSD status, and chronic pain.
O’Grady, M.A., Elkington, K.S., Robson, G. et al. Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators. Subst Abuse Treat Prev Policy 19, 12 (2024). https://doi.org/10.1186/s13011-024-00593-y
Background
People with opioid use disorder (OUD) are frequently in contact with the court system and have markedly higher rates of fatal opioid overdose. Opioid intervention courts (OIC) were developed to address increasing rates of opioid overdose among court defendants by engaging court staff in identification of treatment need and referral for opioid-related services and building collaborations between the court and OUD treatment systems. The study goal was to understand implementation barriers and facilitators in referring and engaging OIC clients in OUD treatment.
Shared by Kwadwo Adu Boakye-Yiadom
- 17 January 2024
Format
ISSUP Webinar
ISSUP Kazakhstan presents Its webinar on the principles of harm reduction for patients. This webinar delves deeper into opioid agonist maintenance therapy.
Shawna Narayan, Hana Brath, Danielle Di Marco, Malcolm Maclure, Rita McCracken & Jan Klimas (2023) “I’m almost opioid-a-phobic”: family medicine residents’ perceptions of enhancing opioid analgesic and agonist treatment training in a Canadian setting, Education for Primary Care, 34:3, 161-167, DOI: 10.1080/14739879.2023.2204310
Purpose
As deaths from the illicit drug poisoning crisis continue to rise in Canada, increasing the number of healthcare professionals qualified to effectively prescribe opioids could be beneficial. The willingness of family medicine residents to undertake structured training in prescribing opioids for Opioid Agonist Treatment (OAT) and pain management have not been well described.
Materials and methods
Family medicine residents (n = 20) in British Columbia, Canada, were asked about their experience with and willingness to enrol in OAT training. Informed by the Consolidated Framework...
The ASSIST package, which consists of a brief questionnaire, a guide for health professionals on how to use the questionnaire in detecting and responding to substance use and also a self-help manual for cutting down or stopping substance use, is the result of more than 10-years work by WHO and an international group of researchers in the framework of the WHO ASSIST project. It is WHO’s response to the growing demand for guidance on how to best manage problems of substance use in non specialist health care settings. This approach, quick and easy to learn, useful for all substances including...
Shared by James Harvey
(ISSUP staff) - 6 November 2023
Event Date
Location:
Washington, D.C.
United States
The Inter-American Commission on Drug Abuse Control (CICAD), the Valencia, Spain City Council, and the Pan-American Health Organization (PAHO) invite you to join the webinar “New guidelines for the health management of opiates” this Tuesday, November 7, starting at 10:00 (Washington, DC time).
Shared by James Harvey
(ISSUP staff) - 10 October 2023
Format
Guide
This 35-minute module focuses on how primary care providers can navigate the changing landscape of opioid use disorder in relation to synthetic opioids.
Rolová, G., Eide, D., Gabrhelík, R. et al. Gender differences in physical morbidity in opioid agonist treatment patients: population-based cohort studies from the Czech Republic and Norway. Subst Abuse Treat Prev Policy 18, 47 (2023). https://doi.org/10.1186/s13011-023-00557-8
Background: Physical health problems are common in people receiving opioid agonist treatment (OAT). A study was conducted on these health issues in OAT patients in the Czech Republic and Norway from 2010 to 2019, with a focus on gender differences.
Methods: In this study, it was a population-based cohort study that linked multiple health records to investigate physical diseases (using ICD-10 codes) in patients receiving OAT in the Czech Republic (4,280 patients) and Norway (11,389 patients) from 2010 to 2019. A gender-stratified analysis was performed.
The event is jointly organized by the United Nations Office on Drug and Crime (UNODC) Civil Society Unit and the Vienna NGO Committee on Drugs (VNGOC).
Ms Chloe Carpientier (Chief, UNODC Drugs Research Section) will present the main...